Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-12-2017 | Editorial

Saving costs in cancer patient management through molecular imaging

Authors: Carl von Gall, Piotr Maniawski, Fred Verzijlbergen, Ignasi Carrio, Thomas Beyer, Antonis Kalemis

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 13/2017

Excerpt

Precision medicine is the future of clinical medicine where one-size-fits-all healthcare guidelines are refined to fit the needs of specific patient groups and even individuals, using molecular, genetic, proteomic and/or other types of data acquired from different diagnostic procedures at different stages of the disease. The ultimate goal is to anticipate and prevent disease in the healthy and to precisely diagnose and treat disease in the ill. However, the success of precision medicine depends on having accurate tests that identify patients who can benefit from expensive, targeted therapies [1]. One of the prominent tools of personalised medicine is molecular imaging, which has the potential to drive tomorrow’s healthcare by lowering healthcare costs and improving health outcomes. …

Margaret A, Hamburg MD, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–4.CrossRef

Gerke O, Hermansson R, Hess S, Schifter S, Vach W, Hoilund-Carlsen PF. Cost-effectiveness of PET and PET/computed tomography: a systematic review. PET Clinic. 2015;10:105–214.CrossRef

Lardinois D, Weder W, Hany T, Kamel E, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with Itegrated positron-emission tomography and computed Tomograph. N Engl J Med. 2003;348:2500–7.CrossRefPubMed

Søgaard R, Fischer BM, Moresnesn J, Højgaard L, Lassen U. Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial. Eur J Nucl Med Mol Imaging. 2011;38:802–9.CrossRefPubMed

Gould MK, Sanders GD, Barnett PG, et al. Cost effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med. 2003;138(9):724–35.CrossRefPubMed

Steenbakkers RJHM, Borst GR, van Herk M, Bartelink H. Improving prediction of radiotherapy response and optimizing target definition by using FDG-PET for lung cancer patients. Medica Mundi 2007;51(2+3):57–63.

Cohade C, Osman M, Leal J, Wahl R. Direct comparison of ¹⁸F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797–803.PubMed

LeJeune C, Bismuth M, Conroy T, Zanni C, Bey P, Bedenne L, et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the Management of Metachronous Liver Metastases of colorectal cancer. J Nucl Med. 2005;46:2020–8.PubMed

Weiring B, Adang EM, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Nucl Med Commun. 2010;31(11):938–44.

10.

Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374(15):1444–54.CrossRefPubMed

11.

Nanni C, Schiavina R, Boschi S, Ambrosini V, Pettinato C, Brunocilla E, et al. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging. 2013;40(Suppl 1):S11–7. doi:10.1007/s00259-013-2373-3.CrossRefPubMed

12.

Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. Nucl Med. 2011;52(1):81–9. doi:10.2967/jnumed.110.077941.CrossRef

13.

Lutje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5(12):1388–401. doi:10.7150/thno.13348.CrossRefPubMedPubMedCentral

14.

Tagawa S, Milowsky M, Morris M, Vallabhajosula S, Christos P, Akhtar N, et al. Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–91. doi:10.1158/1078-0432.CCR-13-0231.CrossRefPubMedPubMedCentral

15.

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2016;58(1):85–90. doi:10.2967/jnumed.116.183194.CrossRefPubMed

16.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Muelle SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048–58. doi:10.1200/JCO.2013.53.5229.CrossRefPubMedPubMedCentral

17.

Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325–9. doi:10.1007/s00259-003-1375-y.CrossRefPubMed

18.

Cerci JJ, Trindade E, Pracchia LF, Pitella FA, Linardi CC, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin’s lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol. 2010;28(8):1415–21. doi:10.1200/JCO.2009.25.4367.CrossRefPubMed

19.

Matthews PM, Rabiner EA, Passchier J, Gunn RN. Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol. 2011;73(2):175–86. doi:10.1111/j.1365-2125.04085.x.CrossRef

20.

Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nature Reviews. 2008;7:591–607. doi:10.1038/nrd2290.PubMed

21.

Iagaru A, Chen X, Gambhir SS. Molecular imaging can accelerate anti-Angiogenic drug development and testing. Nat Clin Pract Oncol. 2007;4(10):556–7.CrossRefPubMed

22.

Cho SH, Kim SI. Personalized medicine in breast cancer: a systematic review. J Breast Cancer. 2012;15(3):265–72.CrossRefPubMedPubMedCentral

23.

Kurian A, et al. A cost-effectiveness analysis of adjuvant Trastuzumab regimens in early HER2/neu–positive breast cancer. J Clin Oncol. 2007;25:634–41. doi:10.1200/JCO.2006.06.3081.CrossRefPubMed

24.

Garrison L, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007;110:489–98. doi:10.1002/cncr.22806.CrossRefPubMed

25.

Silberstein EB. Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011. J Nucl Med. 2014;55(8):1308–10. doi:10.2967/jnumed.114.138057.CrossRefPubMed

26.

Gmeiner ST, Fettich J, Zver S, Mlinaric-Rascan I, Hojker S, Socan A, et al. 99mTc-labelled rituximab, a new non-Hodgkin’s lymphoma imaging agent: first clinical experience. Nucl Med Commun. 2008;29(2):1059–65. doi:10.1097/MNM.0b013e3283134d6e.CrossRef

27.

Camacho X, Machado CL, Garcia MF, Gambini JP, et al. Technitium-99m- or cy7-labeled rituximab as an imaging agent for non-Hodgkin lymphoma. Oncology. 2017;92(4):229–42. doi:10.1159/000452419.CrossRefPubMed

28.

Yin G, Lam CK, Shi H. Bayesian randomized clinical trials: From fixed to adaptive design. Contemp Clin Trials. 2017;59:77-86

Title: Saving costs in cancer patient management through molecular imaging
Authors: Carl von Gall
Piotr Maniawski
Fred Verzijlbergen
Ignasi Carrio
Thomas Beyer
Antonis Kalemis
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 13/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3804-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Saving costs in cancer patient management through molecular imaging

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 13/2017

18F-FDG PET/CT of extensive rheumatoid nodulosis

Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease

A pilot study for texture analysis of 18F-FDG and 18F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery

Diagnostic accuracy of an artificial neural network compared with statistical quantitation of myocardial perfusion images: a Japanese multicenter study

Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET

A kinetic solution for the paradoxical difference between F-Dopa and methionine